Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 30   

Articles published

GSK 1,671.81 +1.31 (0.08%)
price chart
GlaxoSmithKline settles healthcare fraud case for $3 billion
A GlaxoSmithKline logo is seen outside one of its buildings in west London in this February 6, 2008 file photograph. GlaxoSmithKline Plc has agreed to plead guilty to criminal charges and pay $3 billion to settle the largest case of healthcare fraud in ...
GlaxoSmithKline to pay $3billion fine after pleading guilty to healthcare ...  Daily Mail
Glaxo Agrees to Pay $3 Billion in Fraud Settlement  New York Times
Hikma Beats GSK, Pfizer In Argatroban IP Infringement Row
Law360, New York (July 31, 2012, 7:17 PM EDT) -- GlaxoSmithKline PLC and Pfizer Inc. on Tuesday failed to stop Hikma Pharmaceutical Co.
GlaxoSmithKline to pay $3 billion in fines, the largest health care fraud ...
The Justice Department said Monday that GlaxoSmithKline PLC will plead guilty to promoting popular antidepressants Paxil and Wellbutrin for unapproved uses.
Glaxo in $3 Billion Settlement  Wall Street Journal
3 UK Stocks With US-Style Dividends And No Tax Withholding For A Dividend ...
... British multinationals in three diverse sectors that pay American-style quarterly dividends that remain stable with consistent growth from year to year: Royal Dutch Shell PLC Class B (RDS.
GSK clinches deal to buy Human Genome for $3 billion
LONDON/BOSTON GlaxoSmithKline Plc is to acquire its long-time partner Human Genome Sciences Inc for a sweetened offer of about $3 billion, ending on friendly terms a three-month hostile pursuit of the U.S.
GlaxoSmithKline to acquire Human Genome Sciences
After spurning a hostile takeover bid from GlaxoSmithKline PLC in April, Human Genome Sciences Inc. said Monday it agreed to be bought by the biopharmaceutical giant for a more lucrative offer valued at $3.6 billion.
HGS Agrees to $3.6B GSK Buyout; Deal Inked at $14.25 Per Share  BioWorld Online
Big Pharma is in big trouble – or at least it should be
Landmark: GlaxoSmithKline Plc has agreed to plead guilty to criminal charges and pay $3billion to settle the largest case of healthcare fraud in U.S.
Glaxo Tries to Shake Marketing Questions on Advair
GlaxoSmithKline PLC's $3 billion criminal and civil settlement with the U.S. government this week raises questions about the future of asthma treatment Advair—the company's biggest moneymaker and one of the top-selling drugs in the world.
Mark Luschini: European Stocks Are A Generational Buying Opportunity (VGK, EWG)
“If you look at Euro-related equities, in terms of their valuation, over the top of U.S. valuations, that disparity is at a 40-year low,” says Mark Luschini, chief investment strategist at Janney Montgomery.
Bristol Myers Squibb, AstraZeneca Join Forces in $7B Deal for Amylin
One more billion-dollar-plus deal waiting in the wings: GlaxoSmithKline plc (GSK), of London, made an unsolicited $2.6 billion cash offer to acquire Human Genome Sciences Inc., of Rockville, Md.